全文获取类型
收费全文 | 5046篇 |
免费 | 437篇 |
国内免费 | 13篇 |
专业分类
耳鼻咽喉 | 35篇 |
儿科学 | 234篇 |
妇产科学 | 165篇 |
基础医学 | 751篇 |
口腔科学 | 109篇 |
临床医学 | 426篇 |
内科学 | 1060篇 |
皮肤病学 | 110篇 |
神经病学 | 386篇 |
特种医学 | 498篇 |
外科学 | 580篇 |
综合类 | 123篇 |
一般理论 | 3篇 |
预防医学 | 417篇 |
眼科学 | 74篇 |
药学 | 299篇 |
1篇 | |
中国医学 | 6篇 |
肿瘤学 | 219篇 |
出版年
2022年 | 31篇 |
2021年 | 65篇 |
2020年 | 29篇 |
2019年 | 75篇 |
2018年 | 81篇 |
2017年 | 85篇 |
2016年 | 60篇 |
2015年 | 79篇 |
2014年 | 126篇 |
2013年 | 153篇 |
2012年 | 236篇 |
2011年 | 225篇 |
2010年 | 147篇 |
2009年 | 155篇 |
2008年 | 181篇 |
2007年 | 240篇 |
2006年 | 216篇 |
2005年 | 169篇 |
2004年 | 184篇 |
2003年 | 166篇 |
2002年 | 151篇 |
2001年 | 131篇 |
2000年 | 82篇 |
1999年 | 138篇 |
1998年 | 115篇 |
1997年 | 114篇 |
1996年 | 118篇 |
1995年 | 90篇 |
1994年 | 77篇 |
1993年 | 84篇 |
1992年 | 75篇 |
1991年 | 59篇 |
1990年 | 74篇 |
1989年 | 103篇 |
1988年 | 93篇 |
1987年 | 107篇 |
1986年 | 124篇 |
1985年 | 128篇 |
1984年 | 85篇 |
1983年 | 69篇 |
1982年 | 61篇 |
1981年 | 70篇 |
1980年 | 67篇 |
1979年 | 45篇 |
1978年 | 50篇 |
1977年 | 53篇 |
1976年 | 47篇 |
1975年 | 37篇 |
1974年 | 27篇 |
1973年 | 34篇 |
排序方式: 共有5496条查询结果,搜索用时 15 毫秒
1.
Isolated patellofemoral arthritis is an increasingly recognized entity, and is usually associated with previous patellofemoral dysplasia or instability. Patellofemoral arthroplasty (PFA) has evolved significantly in recent years, both in terms of implant design and importantly in the understanding of appropriate patient selection. This review outlines the indications and investigations for PFA, provides a brief history of the development of contemporary implants, and presents the clinical outcomes for the prostheses most commonly used in the UK. In addition, it provides a detailed surgical technique for implantation of an onlay implant, with tips on how to optimize patellofemoral biomechanics and thus achieve a consistently good outcome. 相似文献
2.
Mithun Sattur Clayton Korson Fraser Henderson Stephen Kalhorn 《The American journal of emergency medicine》2019,37(5):1005.e1-1005.e2
Occipital spur is an abnormal bony outgrowth of the external occipital protuberance (EOP). We describe an interesting and previously unreported case of fracture of an occipital spur following trauma. Our 20-year-old male patient was treated in the emergency department (ED) and discharged home without complication. Neurosurgical consultation was obtained but is not requisite for these injuries. Greater awareness of this unique presentation may help to expedite future emergency department treatment. 相似文献
3.
4.
RA O. Hempel 《Notfall & Rettungsmedizin》2007,10(5):367-371
Legal uncertainties for emergency vehicle drivers can be avoided when fundamental rules are established. In particular, differentiation of special rights and rights of way is essential. Inherent in both is the urgency necessary to save human lives. The right of way signaled by flashing blue lights and siren does not however justify traffic violations but signifies rather a request to other traffic participants. In contrast, special rights require no announcement and constitute a justifiable reason for traffic violations. Even so they do not allow that other traffic participants be endangered or harmed. Adherence to these basic principles can prevent legal misinterpretations as well as rigid adoption of inflexible standards of behavior. 相似文献
5.
RA Mag. Dr. C. Gepart 《Notfall & Rettungsmedizin》2007,10(4):289-292
Austria’s new Living Wills Act (Patientenverfügungsgesetz, or PatVG) that came into effect on 1st of June 2006, is the first law in Austria to regulate the controversial issue of living wills. The PatVG provides for a right to refuse future medical treatment by making an advance directive in the form of a living will that is either binding or “to be taken into consideration”. However, the establishment of a binding living will is governed by strict criteria as regards form and content, and both a medical doctor and a legal expert must be involved. Compliance with a living will is not allowed where there is a legal obligation to give medical treatment. There is also a legal obligation to give medical treatment in emergency situations where the time involved in looking for a living will could seriously endanger the health or the life of a patient. 相似文献
6.
Jocivania O da Silva Renata S Fernandes Fábio K Ticli Clayton Z Oliveira Maurício V Mazzi Jo?o J Franco Silvana Giuliatti Paulo S Pereira Andreimar M Soares Suely V Sampaio 《Toxicon》2007,50(2):283-291
We report here the antiproteolytic and antihemorrhagic properties of triterpenoid saponin inhibitors, named macrolobin-A and B, from Pentaclethra macroloba, against Bothrops snake venoms. The inhibitors were able to neutralize the hemorrhagic, fibrin(ogen)olytic, and proteolytic activities of class P-I and P-III metalloproteases isolated from B. neuwiedi and B. jararacussu venoms. Clotting and fibrinogenolytic activities induced by snake venoms and isolated thrombin-like enzymes were partially inhibited. Furthermore, the potential use of these inhibitors to complement antivenom therapy as an alternative treatment and/or used as molecular models for development of new therapeutical agents in the treatment of snake bite envenomations needs to be evaluated in future studies. 相似文献
7.
Growth hormone signalling: sprouting links between pathways, human genetics and therapeutic options.
Iwona Pilecka Andrew Whatmore Rob Hooft van Huijsduijnen Benoit Destenaves Peter Clayton 《Trends in Endocrinology and Metabolism》2007,18(1):12-18
Our molecular understanding of growth hormone-induced signal transduction has improved significantly over the past decades. At the same time, human population genetics and the analysis of genetically engineered animals have led to the discovery of genes that control specific aspects of the overall growth process. Although, currently, growth disorders are still diagnosed and treated on empirical bases, it might soon be possible to stratify patients predominantly by genetic defect, with treatment based on our molecular understanding of the role of the affected gene in the disease. 相似文献
8.
9.
Ohne Zusammenfassung 相似文献
10.
Both cyproterone acetate (CPA) and the gonadotrophin-releasing hormone
agonist (GnRHa) have been shown to be effective for the treatment of
hirsutism. We wished to compare the effectiveness of CPA in two standard
doses with GnRHa and add-back therapy and to compare the length of
remission after these treatments. A total of 60 hirsute hyperandrogenic
women was assigned to the following treatment groups: CPA 2 mg with 35
microg of ethinylestradiol for 21 days each month (Diane group), CPA 50 mg,
days 5-15, and ethinylestradiol 50 microg, days 5-25, each month (CPA
group) or Decapeptyl 3.75 mg i.m. every 28 days with the addition of
conjugated oestrogen 0.625 mg, days 1-21, and medroxyprogesterone acetate
10 mg, days 12-21 (GnRHa group). Hirsutism was graded by the
Ferriman-Gallwey-Lorenzo (FGL) index and anagen hair shaft diameters and
serum luteinizing hormone (LH) and testosterone were assessed before and
every 3 months during and after treatment. All women were treated for 1
year with 1 year follow-up. At baseline hirsutism and endocrine patterns
were similar in all groups. After one year of treatment, hirsutism
decreased in all groups but the changes were greater (P <0.05) in the
CPA and GnRHa groups than in the Diane group. Serum LH and testosterone
were lowest in the GnRHa group. After withdrawal, hirsutism increased
rapidly in the Diane and CPA groups and after 6 months, FGL scores and hair
shaft diameters were similar to pretreatment values. In the GnRHa group,
hirsutism increased more gradually and after 1 year of withdrawal, FGL
scores and hair diameters were significantly (P <0.05) less than
pretreatment values. Serum LH and testosterone increased rapidly in all
three groups reaching pretreatment values by 6 months. These data suggest
equal efficacy of the GnRHa and the high dose CPA regimen for the treatment
of hirsutism in hyperandrogenic women. GnRHa with add-back treatment
appears to result in a longer remission of hirsutism in comparison with
CPA.
相似文献